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Implantable cardioverter defibrillators (ICDs) are effective for
both primary and secondary prevention of sudden cardiac
death. For patients with reduced left ventricular ejection frac-
tion (LVEF) caused by ischaemic or non-ischaemic aetiology,
ICDs have received a class I indication in the recent European
and American guidelines (reviewed by Maass and Van
Veldhuisen [1]). Selection of patients has become simple, as
we have to relymostly on LVEFwith few extra criteria such as
functional class. The disadvantage of simple criteria is the
offset of high sensitivity with low specificity. Using the cur-
rent guidelines, many patients who receive ICDs especially
for primary prevention will never receive appropriate ICD
therapies. Utilisation of ICDs according to the guidelines
might be offset by severe complications, not only peri-
operatively but also in the long term. Inappropriate ICD
therapy, lead problems, and primary or secondary infection
of ICD systems can all lead to morbidity and mortality. Fur-
thermore, cost-effectiveness of primary prevention ICDs has
recently been questioned. The DO-IT registry will investigate
outcomes of primary prevention ICDs in the Netherlands and
we are eagerly awaiting these results to justify implantations
in this situation. Current data suggest that real-life ICD ther-
apy in Dutch centres is beneficial even though certain patients
might benefit less [2].
Which diagnostic tests can be used to govern ICD implan-
tations? Risk prediction is even more important for non-
ischaemic cardiomyopathy as the evidence for prophylactic
ICD implantation is rather weak. Tests should be easy to
perform and results should be unambiguous.
Currently, LVEF is the gold standard to indicate a patient
for ICD implantation. The test that should be used to quantify
LVEF, however, is not mentioned in the guidelines and results
from echocardiography, nuclear imaging or magnetic reso-
nance imaging might be divergent.
Simple clinical characteristics such as functional class and
history of syncope are easy to record but not unambiguous.
Functional class is very subjective and neurocardiogenic syn-
cope is very common and occurs often without underlying
cardiac pathology. In addition to functional class, renal insuf-
ficiency, chronic obstructive pulmonary disease, age and sex
all influence risk of sudden death. The predictive value, how-
ever, is offset by an increase in all-cause mortality, and risk
reduction by ICDs is low in high-risk populations. High-risk
patients derive no benefit from non-resynchronisation ICD
therapy [3]. Even though increasing age leads to increase in
all-cause mortality, age per se is a poor predictor of outcome
of ICD therapy [4].
Registration of spontaneous non-sustained ventricular
tachycardias (VTs) via Holter monitoring is also simple but
sensitivity might also be low with a single 24-hour recording.
Furthermore, the prognostic value of spontaneous VTs has
only been demonstrated in depressed ejection due to ischae-
mic aetiology whereas results in patients with non-ischaemic
cardiomyopathy are less clear. Inducibility of monomorphic
VTs by programmed electrical stimulation might be of pre-
dictive value but results from studies are not consistent espe-
cially for non-ischaemic cardiomyopathy and this test is inva-
sive and not particularly easy to perform outside of specialised
centres.
Genetics are currently used to confirm the diagnosis in
familial heart diseases such as hypertrophic and dilated car-
diomyopathy. In dilated cardiomyopathy, common mutations
in Dutch patients have malignant phenotypes such as lamin
A/C and phospholamban. In these patients, ICD implantation
can be useful even if decline in LVEF has not yet reached
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35%.Most likely, the near future will reveal common disease-
modifying polymorphisms that render their carriers at in-
creased risk of sudden death if they develop heart disease.
We will have to wait for identification of such genetic modi-
fiers but once they are known testing would fulfil the criterion
of simplicity and possibly unambiguity.
Several parameters of the electrocardiogram have been
used to predict risk: resting heart rate, heart rate recovery,
heart rate variability or turbulence, QT dispersion or microvolt
Twave alternans (MTWA). In this issue of the journal, Kraaier
et al. test whether exercise MTWA can be used to identify
patients at high risk of death or appropriate ICD shocks [5].
MWTA testing did not predict mortality but test ineligibility
was a significant predictor of mortality. A significant portion
of patients were ineligible for this test. Atrial fibrillation is an
exclusion criterion and is common in heart failure patients
indicated for ICD. Furthermore, MWTA testing involves an
exercise protocol. This test, therefore, does not qualify as
simple. The current study also shows that MWTA is also not
unambiguous.
Where are we headed with prophylactic ICD implanta-
tions? Cardiology has recently seen a dramatic increase in
the use of scores to govern diagnostics and treatment. Oral
anticoagulation therapy is governed by the CHADS-VASc
score, cardiothoracic surgery risk is evaluated with the
EUROSCORE, and we use the GRACE score to evaluate risk
in patients with acute coronary syndromes. Why are we not
using a risk score to predict efficacy of ICDs? We urgently
need more than LVEF to decide on which patients should
receive an ICD. In the current situation, we might implant
patients at low risk who might never receive adequate ICD
therapies and are at risk to develop serious complications. On
the other hand, patients with an LVEF presumed to be above
35% might be at risk of sudden cardiac death and not receive
this life-saving therapy. The prognosis of patients with heart
failure with preserved ejection fraction (HFPEF) is not much
better than that of patients with depressed ejection fraction [1].
Sudden cardiac death is also common in HFPEF patients. We
really need additional diagnostic tests and risk scores to gov-
ern ICD implantation irrespective of ejection fraction or at
least with it being just one of the factors taken into
consideration.
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